COVID-19 Is an Endothelial Disease: Implications of Nitric Oxide
- 4 March 2021
- book chapter
- review article
- Published by Springer Science and Business Media LLC
- Vol. 1321, 109-113
- https://doi.org/10.1007/978-3-030-59261-5_9
Abstract
Endothelial cells are a clinically important infection site for COVID-19, both as a mechanism for disease pathogenesis and as a therapeutic target. People with dysfunctional endothelium, defined by nitric oxide deficiency, appear to have a more severe disease course. As such, nitric oxide has therapeutic potential to mitigate COVID-19 severity. Inhaled nitric oxide appears to improve outcomes, although this strategy neglects systemic endothelium. Meanwhile, early studies have documented that endothelial protective medications, such as the administration of statins and ACE-inhibitors, are associated with less severe disease and reduced mortality. Importantly, these medications augment endothelial sources of nitric oxide, which may explain this effect.Keywords
This publication has 27 references indexed in Scilit:
- ACE inhibition enhances bradykinin relaxations through nitric oxide and B1 receptor activation in bovine coronary arteriesBiological Chemistry, 2013
- The Vascular Endothelium and Human DiseasesInternational Journal of Biological Sciences, 2013
- Effects of angiotensin receptor blockers on endothelial nitric oxide release: the role of eNOS variantsBritish Journal of Clinical Pharmacology, 2012
- Simvastatin Therapy Reduces Prooxidant‐Antioxidant Balance: Results of a Placebo‐Controlled Cross‐Over TrialLipids, 2011
- Dual effect of nitric oxide on SARS-CoV replication: Viral RNA production and palmitoylation of the S protein are affectedVirology, 2009
- Anti-atherogenic effect of statins: role of nitric oxide, peroxynitrite and haem oxygenase-1British Journal of Pharmacology, 2009
- Different Effects of Angiotensin Converting Enzyme Inhibitors on Endothelin-1 and Nitric Oxide Balance in Human Vascular Endothelial Cells: Evidence of an Oxidant-Sensitive PathwayMediators of Inflammation, 2008
- Inhalation of Nitric Oxide in the Treatment of Severe Acute Respiratory Syndrome: A Rescue Trial in BeijingClinical Infectious Diseases, 2004
- Nitric oxide donors inhibit the coxsackievirus B3 proteinases 2A and 3C in vitro, virus production in cells, and signs of myocarditis in virus-infected miceMedical Microbiology and Immunology, 2003
- Nitric oxide and murine coxsackievirus B3 myocarditis: Aggravation of myocarditis by inhibition of nitric oxide synthaseJournal of the American College of Cardiology, 1996